Ophthalmic Business News

Oculis has completed enrollment in the first stage of a phase 3 study evaluating a topical eye drop for the treatment of diabetic macular edema, according to a press release.

The FDA granted orphan drug designation to IOA-244 for the treatment of uveal melanoma, according to a press release from iOnctura.

In this episode, I share my top five predictions for 2023 in the field of ophthalmology.

Bausch + Lomb and Glaucoma Research Foundation have launched the “Screen, Protect, Cure” campaign to raise glaucoma awareness.

In other articles for Residency for Retirement, we have explained that permanent life insurance, also called cash value life insurance, has tremendous tax, wealth accumulation, asset protection and estate planning benefits.

Orasis Pharmaceuticals has submitted a new drug application to the FDA for CSF-1, its investigational eye drop candidate for presbyopia, according to a press release.

NEW YORK — In this Healio Video Perspective at OSN New York, Carey Kelson and John Steenbakkers discuss Trukera Medical’s recently launched ScoutPro osmolarity system.

Aldeyra has submitted a new drug application to the FDA for ADX2191 for the treatment of primary vitreoretinal lymphoma, according to a company press release.

Opus Genetics has acquired the rights to develop two preclinical-stage AAV-based gene therapy product candidates for inherited retinal diseases from Iveric Bio, according to a company press release.

This year’s top ophthalmic business article discussed ophthalmology’s venture into the metaverse.